for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Bristol-Myers Squibb Co

BMY

Latest Trade

65.62USD

Change

0.16(+0.24%)

Volume

2,476,079

Today's Range

65.13

 - 

65.73

52 Week Range

54.07

 - 

67.16

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
65.46
Open
65.42
Volume
2,476,079
3M AVG Volume
248.85
Today's High
65.73
Today's Low
65.13
52 Week High
67.16
52 Week Low
54.07
Shares Out (MIL)
2,231.00
Market Cap (MIL)
144,866.90
Forward P/E
8.74
Dividend (Yield %)
3.02

Next Event

Q2 2021 Bristol-Myers Squibb Co Earnings Release

Latest Developments

More

U.S. Food And Drug Administration Accepts For Priority Review Bristol Myers Squibb’s Application For Opdivo (Nivolumab)

Bristol-Myers Squibb Reports Qtrly GAAP Earnings Per Share $0.89

Bristol Myers Presents Positive Data From Two Pivotal Phase 3 Psoriasis Studies

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Bristol-Myers Squibb Co

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. Its products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world. Its subsidiaries are Celgene Corp and MyoKardia, Inc.

Industry

Biotechnology & Drugs

Contact Info

430 E 29th St Fl 14

NEW YORK, NY

10016-8367

United States

+1.212.5464000

https://www.bms.com/

Executive Leadership

Giovanni Caforio

Chairman of the Board, Chief Executive Officer

David V. Elkins

Executive Vice President and Chief Financial Officer Member of the Leadership Team

Ann M. Powell

Chief Human Resource Officer, Senior Vice President Member of the Leadership Team

Sandra Leung

Executive Vice President, General Counsel, Member of the Leadership Team

Christopher S. Boerner

Executive Vice President and Chief Commercial Officer, Member of the Leadership Team

Key Stats

1.89 mean rating - 19 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

22.6K

2019

26.1K

2020

42.5K

2021(E)

46.1K
EPS (USD)

2018

3.980

2019

4.690

2020

6.440

2021(E)

7.427
Price To Earnings (TTM)
--
Price To Sales (TTM)
3.38
Price To Book (MRQ)
3.85
Price To Cash Flow (TTM)
31.70
Total Debt To Equity (MRQ)
123.07
LT Debt To Equity (MRQ)
118.35
Return on Investment (TTM)
-6.05
Return on Equity (TTM)
-5.13

Latest News

Latest News

Bristol Myers to pay up to $1.38 billion to develop, sell Agenus's cancer therapy

Drugmaker Bristol Myers Squibb will pay biotech firm Agenus Inc up to $1.38 billion to exclusively develop and commercialize its experimental cancer drug, AGEN1777, the companies said on Tuesday.

Bristol Myers first-quarter earnings miss expectations as cancer drugs underperform

Bristol Myers Squibb Co reported lower-than-expected first-quarter profit on Thursday as sales of its high margin cancer drugs Revlimid and Opdivo fell short of Wall Street estimates.

Bristol-Myers to pay $75 mln to settle claims of underpaying Medicaid rebates

Bristol-Myers Squibb Co has agreed to pay $75 million to the U.S. and state governments to resolve claims that it knowingly underpaid rebates it owed to state Medicaid programs, federal prosecutors announced Thursday.

Bluebird bio sets list price for multiple myeloma therapy at $419,500

Bluebird bio Inc < BLUE.O> said on Monday it has set at $419,500 the wholesale list price of its newly approved multiple myeloma therapy developed with Bristol-Myers Squibb Co.

U.S. FDA approves Bristol-Myers Squibb's multiple myeloma therapy

The U.S. Food and Drug Administration has approved Bristol-Myers Squibb Co and bluebird bio Inc's multiple myeloma therapy, ide-cel, acquired as part of its $74 billion buyout of Celgene, the drugmakers said in a joint statement late on Friday.

Bristol-Myers, Sanofi ordered to pay Hawaii $834 million over Plavix warning label

A judge in Hawaii on Monday ordered Bristol-Myers Squibb Co and Sanofi SA to pay more than $834 million to the state for failing to warn non-white patients properly of health risks from its blood thinner Plavix.

Bristol-Myers, Sanofi ordered to pay Hawaii $834 mln over Plavix warning label

Bristol-Myers Squibb Co and Sanofi SA were ordered by a U.S. judge on Monday to pay more than $834 million to the state of Hawaii for failing to properly warn non-white patients of health risks from its blood thinner Plavix.

FDA approves Bristol-Myers' gene therapy for white blood cell cancer

The U.S. Food and Drug Administration (FDA) on Friday approved Bristol-Myers Squibb's cell-based gene therapy, Breyanzi, to treat adults with a type of cancer that starts in certain cells of the immune system.

FDA approves Bristol-Myers' gene therapy for white blood cell cancer

The U.S. Food and Drug Administration (FDA) on Friday approved Bristol-Myers Squibb's cell-based gene therapy, Breyanzi, to treat adult patients with certain types of large B-cell lymphoma who have not responded to, or have relapsed after, at least two other types of systemic...

Bristol Myers fourth quarter profit tops Street view on strong sales from Celgene drugs

Bristol Myers Squibb Co reported higher-than-expected fourth quarter earnings on Thursday on strong sales from the blood cancer drugs it acquired through its $74 billion purchase of Celgene in 2019.

Bristol Myers psoriasis drug succeeds in late-stage study

Bristol Myers Squib said on Tuesday its experimental oral drug for plaque psoriasis significantly reduced the extent and severity of the skin condition and was more effective than a placebo and Amgen Inc's Otezla.

Bristol Myers sees up to $25 billion a year of new revenue from current drug pipeline

Bristol Myers Squibb said on Monday that its current drug pipeline has the ability to replace up to $25 billion a year in lost revenue from patent expirations by the end of the decade.

FDA delays decision on Bristol Myers cancer therapy due to COVID-19 travel curbs

Bristol Myers Squibb said on Monday the U.S. health regulator has deferred a decision on an experimental blood cancer therapy that it acquired in the $74 billion buyout of Celgene due to coronavirus-related travel restrictions.

Better-than-expected sales drive Bristol Myers earnings

Bristol Myers Squibb Co on Thursday posted better-than-expected third-quarter earnings, with most of its top-selling drugs outperforming Wall Street forecasts, as many Americans resumed routine medical care they had put off earlier in the coronavirus pandemic.

Bristol Myers psoriasis drug succeeds in late-stage study

Bristol Myers Squibb Co said on Tuesday its experimental plaque psoriasis oral drug proved more effective in clearing moderate to severe cases of the skin condition than placebo or Amgen Inc's Otezla in a late-stage study.

NIH tests therapies to help cut hospital stays for COVID-19 patients

The U.S. National Institutes of Health (NIH) has started a late-stage trial to evaluate if immune-modulating therapies from three drugmakers can help reduce the need for ventilators for COVID-19 patients and shorten their hospital stay.

Bristol Myers' Opdivo succeeds in late-stage lung cancer trial

Bristol Myers Squibb Co said on Wednesday its cancer drug Opdivo plus chemotherapy helped more patients with a form of lung cancer become free of the disease versus chemotherapy alone in a late-stage trial. Significantly more non-small cell lung cancer (NSCLC) patients receiving...

Bristol Myers' Opdivo succeeds in late-stage lung cancer trial

Bristol Myers Squibb Co said on Wednesday its blockbuster cancer immunotherapy, Opdivo, met the main goal of pathologic complete response, or the absence of cancer cells, in a late-stage study in patients with a type of lung cancer.

Healthcare deals keep Big Law busy amid M&A rebound

At least nine law firms scored work on healthcare deals announced this week, capitalizing on a sector that has stayed hot while other industries catch up from the pandemic's economic chill.

Bristol Myers expands heart drug business with $13 billion deal for MyoKardia

Bristol Myers Squibb Co said on Monday it would buy MyoKardia Inc for about $13 billion to bolster its portfolio of heart disease treatments, ahead of the potential loss of sales exclusivity of some of its blockbuster drugs.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up